Connor, Clark & Lunn Investment Management Ltd. Myriad Genetics Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 115,036 shares of MYGN stock, worth $1.71 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
115,036
Previous 21,865
426.12%
Holding current value
$1.71 Million
Previous $534,000
489.51%
% of portfolio
0.02%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MYGN
# of Institutions
251Shares Held
90.7MCall Options Held
100KPut Options Held
34K-
Black Rock Inc. New York, NY15.2MShares$225 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$153 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.72MShares$99.6 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$76.8 Million0.07% of portfolio
-
State Street Corp Boston, MA4.7MShares$69.8 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.2B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...